A preparation method of a pyrimidinylthio-benzoate oxime ester compound and an application thereof are provided. The chemical structural formula of the pyrimidinylthio-benzoate compound is shown in the following formula (I). The preparation method includes step A: preparation of a substituted acetophenone oxime: taking hydroxylamine hydrochloride and a substituted acetophenone as a raw material, adding an alcohol as a solvent, and performing a reaction at 0° C.-80° C. for 1-5 hours under an alkaline condition to obtain the substituted acetophenone oxime; and step B: preparation of the compound: using 2-chloro-6-((4,6-dimethoxypyrimidin-2-yl)thio)benzoic acid and the substituted acetophenone oxime as a raw material, and performing a reaction under an action of an organic solvent, a dehydrating agent and a catalyst at 25° C. for 6-24 hours; after the reaction is completed, performing a suction filtration, and subjecting the filtrate to a decompression distillation and a recrystallization to obtain the compound.

##STR00001##

A preparation method of a pyrimidinylthio-benzoate oxime ester compound and an application thereof are provided. The chemical structural formula of the pyrimidinylthio-benzoate compound is shown in the following formula (I). The preparation method includes step A: preparation of a substituted acetophenone oxime: taking hydroxylamine hydrochloride and a substituted acetophenone as a raw material, adding an alcohol as a solvent, and performing a reaction at 0° C.-80° C. for 1-5 hours under an alkaline condition to obtain the substituted acetophenone oxime; and step B: preparation of the compound: using 2-chloro-6-((4,6-dimethoxypyrimidin-2-yl)thio)benzoic acid and the substituted acetophenone oxime as a raw material, and performing a reaction under an action of an organic solvent, a dehydrating agent and a catalyst at 25° C. for 6-24 hours; after the reaction is completed, performing a suction filtration, and subjecting the filtrate to a decompression distillation and a recrystallization to obtain the compound.

##STR00001##

Compounds for targeting and agents for imaging, prostate-specific membrane antigen (PSMA) are disclosed. Methods of synthesizing compounds and imaging agents, as well as methods for imaging PSMA are also disclosed. The imaging agents disclosed are suitable for PET and SPECT imaging.

Compounds for targeting and agents for imaging, prostate-specific membrane antigen (PSMA) are disclosed. Methods of synthesizing compounds and imaging agents, as well as methods for imaging PSMA are also disclosed. The imaging agents disclosed are suitable for PET and SPECT imaging.

Compounds for targeting and agents for imaging, prostate-specific membrane antigen (PSMA) are disclosed. Methods of synthesizing compounds and imaging agents, as well as methods for imaging PSMA are also disclosed. The imaging agents disclosed are suitable for PET and SPECT imaging.

Compounds for targeting and agents for imaging, prostate-specific membrane antigen (PSMA) are disclosed. Methods of synthesizing compounds and imaging agents, as well as methods for imaging PSMA are also disclosed. The imaging agents disclosed are suitable for PET and SPECT imaging.

Compounds for targeting and agents for imaging, prostate-specific membrane antigen (PSMA) are disclosed. Methods of synthesizing compounds and imaging agents, as well as methods for imaging PSMA are also disclosed. The imaging agents disclosed are suitable for PET and SPECT imaging.

Compounds for targeting and agents for imaging, prostate-specific membrane antigen (PSMA) are disclosed. Methods of synthesizing compounds and imaging agents, as well as methods for imaging PSMA are also disclosed. The imaging agents disclosed are suitable for PET and SPECT imaging.

The present invention relates to compounds of formula (I):

##STR00001##

wherein Q is selected from O or S; R.sup.1 is a non-aromatic heterocyclic group comprising at least one ring nitrogen atom, wherein R.sup.1 is attached to the sulfur atom of the sulfonylurea group by a ring carbon atom, and wherein R.sup.1 may optionally be substituted; and R.sup.2 is a cyclic group substituted at the -position, wherein R.sup.2 may optionally be further substituted.

The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.

The present invention relates to compounds of formula (I):

##STR00001##

wherein Q is selected from O or S; R.sup.1 is a non-aromatic heterocyclic group comprising at least one ring nitrogen atom, wherein R.sup.1 is attached to the sulfur atom of the sulfonylurea group by a ring carbon atom, and wherein R.sup.1 may optionally be substituted; and R.sup.2 is a cyclic group substituted at the -position, wherein R.sup.2 may optionally be further substituted.

The present invention further relates to salts, solvates and prodrugs of such compounds, to pharmaceutical compositions comprising such compounds, and to the use of such compounds in the treatment and prevention of medical disorders and diseases, most especially by the inhibition of NLRP3.